A detailed history of Assetmark, Inc transactions in Medpace Holdings, Inc. stock. As of the latest transaction made, Assetmark, Inc holds 144 shares of MEDP stock, worth $49,347. This represents 0.0% of its overall portfolio holdings.

Number of Shares
144
Previous 187 22.99%
Holding current value
$49,347
Previous $77,000 37.66%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 01, 2024

SELL
$320.58 - $457.29 $13,784 - $19,663
-43 Reduced 22.99%
144 $48,000
Q2 2024

Aug 13, 2024

BUY
$372.0 - $424.34 $4,092 - $4,667
11 Added 6.25%
187 $77,000
Q1 2024

May 06, 2024

SELL
$284.87 - $413.31 $12,534 - $18,185
-44 Reduced 20.0%
176 $71,000
Q3 2022

Nov 01, 2022

SELL
$145.13 - $182.49 $15,238 - $19,161
-105 Reduced 32.31%
220 $35,000
Q2 2022

Aug 03, 2022

SELL
$130.2 - $168.03 $11,066 - $14,282
-85 Reduced 20.73%
325 $49,000
Q4 2021

Feb 14, 2022

SELL
$182.74 - $227.9 $2,923 - $3,646
-16 Reduced 3.76%
410 $89,000
Q2 2021

Aug 16, 2021

BUY
$158.62 - $194.3 $1,586 - $1,943
10 Added 2.4%
426 $75,000
Q1 2021

May 14, 2021

BUY
$132.02 - $168.26 $6,601 - $8,413
50 Added 13.66%
416 $68,000
Q4 2020

Feb 10, 2021

BUY
$109.38 - $149.19 $39,486 - $53,857
361 Added 7220.0%
366 $51,000
Q2 2020

Aug 11, 2020

SELL
$68.08 - $95.68 $136 - $191
-2 Reduced 28.57%
5 $0
Q1 2020

May 12, 2020

SELL
$61.71 - $101.95 $1,481 - $2,446
-24 Reduced 77.42%
7 $1,000
Q4 2019

Feb 11, 2020

BUY
$70.08 - $84.64 $140 - $169
2 Added 6.9%
31 $3,000
Q3 2019

Nov 13, 2019

BUY
$62.38 - $85.89 $1,185 - $1,631
19 Added 190.0%
29 $2,000
Q2 2019

Aug 14, 2019

BUY
$53.64 - $65.42 $214 - $261
4 Added 66.67%
10 $1,000
Q1 2019

May 14, 2019

BUY
$49.38 - $70.58 $296 - $423
6 New
6 $0

Others Institutions Holding MEDP

About Medpace Holdings, Inc.


  • Ticker MEDP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 31,099,900
  • Market Cap $10.7B
  • Description
  • Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, bi...
More about MEDP
Track This Portfolio

Track Assetmark, Inc Portfolio

Follow Assetmark, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Assetmark, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Assetmark, Inc with notifications on news.